Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 1976 - 2000 of 15273 in total

Clofazimine

Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as dapsone, for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloration of the skin...
Approved
Investigational
Matched Description: … , in its clinical use, results in long-lasting discoloration of the skin and bodily fluids. ... It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that ... considered an ineffective treatment in comparison to classic tuberculosis treatments such as [rifampicin] and …
Matched Categories: … dapsone, rifampicin and clofazimine …

Orlistat

The global prevalence of obesity is increasing rapidly. Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical intervention is required. Orlistat is a...
Approved
Investigational
Matched Description: … In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological ... [L11130] This drug is a generally well-tolerated and effective weight-loss aid and is now available in ... life and increasing the cost of healthcare. …
Matched Categories: … Alimentary Tract and Metabolism …

Amrinone

Amrinone (or inamrinone) is a type 3 pyridine phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure.
Approved
Matched Categories: … Calcium-Regulating Hormones and Agents …

Metamfetamine

Metamfetamine (methamphetamine) is a psychostimulant and sympathomimetic drug, and a member of the amphetamine group of sympathomimetic amines. Methamphetamine can induce effects such as euphoria, increased alertness and energy, and enhanced self-esteem. It is a scheduled drug in most countries due to its high potential for addiction and abuse. The...
Approved
Illicit
Withdrawn
Matched Description: … Metamfetamine (methamphetamine) is a psychostimulant and sympathomimetic drug, and a member of the amphetamine ... Methamphetamine can induce effects such as euphoria, increased alertness and energy, and enhanced self-esteem ... It is a scheduled drug in most countries due to its high potential for addiction and abuse. …
Matched Categories: … Psychostimulants, Agents Used for ADHD and Nootropics …

Phenindamine

Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor...
Approved
Matched Description: … of allergies and the common cold. ... those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and ... ears, blurred vision, large pupils, dry mouth, flushing, fever, shaking, insomnia, hallucinations, and …

Silodosin

Silodosin is a selective antagonist of alpha(α)-1 adrenergic receptors that binds to the α1A subtype with the highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder neck, prostate, and prostatic urethra: the α1A subtype accounts for approximately 75% of α1-adrenoceptors in the prostate. Silodosin was first approved by...
Approved
Matched Description: … in Europe and Canada. ... Silodosin is available as oral capsules with common trade names Rapaflo and Urorec. ... highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder neck, prostate, and …
Matched Categories: … Genito Urinary System and Sex Hormones …

Panobinostat

Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat...
Approved
Investigational
Matched Description: … Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Azilsartan medoxomil

Azilsartan medoxomil is a prodrug that is broken down to azilsartan, which belongs in the angiotensin-receptor blocking (ARB) drug class. It is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a relatively recently-developed antihypertensive drug that was first approved by the FDA in February 2011. Many guidelines...
Approved
Investigational
Matched Description: … , primarily strokes and myocardial infarctions. ... guidelines recommend the use of ARBs as first-line therapy when initiating antihypertensive therapy and ... Lowering blood pressure is associated with a reduced risk of fatal and nonfatal cardiovascular events …
Matched Categories: … azilsartan medoxomil and diuretics ... Angiotensin II receptor blockers (ARBs) and diuretics …

Naloxegol

Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antagonist naloxone is that its...
Approved
Matched Description: … naloxone is that its PEGylated structure allows for high selectivity for peripheral opioid receptors and ... It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation …
Matched Categories: … Alimentary Tract and Metabolism …

Sacubitril

Sacubitril is a prodrug neprilysin inhibitor used in combination with valsartan to reduce the risk of cardiovascular events in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction. It was approved by the FDA after being given the status of priority review for on July 7, 2015....
Approved
Matched Iupac: … 3-{[(2S,4R)-1-{[1,1'-biphenyl]-4-yl}-5-ethoxy-4-methyl-5-oxopentan-2-yl]carbamoyl}propanoic acid …
Matched Description: … such as angiotensin I and II, endothelin-1 and peptide amyloid beta-protein. ... ANP and BNP are released under atrial and ventricle stress, which activate downstream receptors leading ... to vasodilation, natriuresis and diuresis. …
Matched Categories: … valsartan and sacubitril ... Amino Acids, Peptides, and Proteins …

Levobetaxolol

Levobetaxolol is a beta-blocker used to lower the pressure in the eye to treat conditions such as glaucoma. It was marketed as a 0.5% ophthalmic solution of levobetaxolol hydrochloride under the trade name Betaxon but has been discontinued.
Approved
Investigational

Dopexamine

Dopexamine has been used in trials studying the diagnostic and treatment of Free Flap, Oral Cancer, Hypotension, Septic Shock, and Head and Neck Cancer.
Approved
Investigational
Matched Description: … , Septic Shock, and Head and Neck Cancer. ... Dopexamine has been used in trials studying the diagnostic and treatment of Free Flap, Oral Cancer, Hypotension …
Matched Categories: … Adrenergic and Dopaminergic Agents …

Protionamide

Prothionamide has been used in trials studying the treatment of MDR-TB and HIV Infections.
Approved
Investigational
Matched Description: … Prothionamide has been used in trials studying the treatment of MDR-TB and HIV Infections. …

Carbocromen

Carbocromen was marketed for use in Germany as a vasodilator, however, it has been discontinued due to the risk of arrhythmia development .
Approved
Withdrawn

Pafolacianine

Pafolacianine, or OTL38, is a folate analogue conjugated with a fluorescent dye that absorbs light in the near-infrared (NIR) spectrum within a range of 760 nm to 785 nm, with a peak absorption of 776 nm. It emits fluorescence within a range of 790 nm to 815 nm with a...
Approved
Investigational
Matched Description: … wavelength allows for deeper penetration of the fluorescent light through tissues for better imaging and ... It is currently under investigation for use in FRα-positive pituitary adenoma, lung cancer,[A242577] and …
Matched Categories: … Folic Acid Analogues …

Bosentan

Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure.
Approved
Investigational
Matched Description: … blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and …
Matched Categories: … Sulfur Compounds ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …

Fulvestrant

Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the...
Approved
Investigational
Matched Description: … It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Atazanavir

Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses per day)...
Approved
Investigational
Matched Description: … Food and Drug Administration (FDA) approved atazanavir on June 20, 2003. ... has lesser effects on the patient's lipid profile (the amounts of cholesterol and other fatty substances ... distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses per day) and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... atazanavir and ritonavir ... atazanavir and cobicistat …

Pilocarpine

A naturally occurring alkaloid derived from the Pilocarpus plants, pilocarpine is a muscarinic acetylcholine agonist.[A262016, A262036] Pilocarpine is associated with parasympathomimetic effects by selectively working on muscarinic receptors. Pilocarpine is used to treat dry mouth and various ophthalmic conditions, including elevated intraocular pressure and glaucoma. The usage of glaucoma by...
Approved
Investigational
Matched Description: … intraocular pressure and glaucoma. ... [A262036] Pilocarpine is used to treat dry mouth and various ophthalmic conditions, including elevated …
Matched Categories: … Antiglaucoma Preparations and Miotics …

Methylnaltrexone

Methylnaltrexone is a pheriphally-acting μ-opioid antagonist that acts on the gastrointestinal tract to decrease opioid-induced constipation without producing analgesic effects or withdrawal symptoms. It is also a weak CYP2D6 inhibitor. FDA approved in 2008.
Approved
Matched Categories: … Alimentary Tract and Metabolism …

Loteprednol

Approved
Experimental
Matched Categories: … loteprednol and antiinfectives …

Ponesimod

Ponesimod is a selective sphingosine 1-phosphate receptor 1 modulator indicated in the treatment of relapsing forms of multiple sclerosis in adults.[A232079,L32709] Ponesimod was developed out of a need for a more selective modulator of sphingosine 1-phosphate receptor 1 than fingolimod. Fingolimod's activity at sphingosine 1-phosphate receptor 3 was suspected to...
Approved
Investigational
Matched Description: … sphingosine 1-phosphate receptor 3 was suspected to be responsible for a portion of it's adverse effects, and …
Matched Categories: … Sulfur Compounds ... Antineoplastic and Immunomodulating Agents …

Dexmethylphenidate

Dexmethylphenidate is the dextrorotary form of methylphenidate introduced in 2002 . It is a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant . It is used for treatment of Attention Deficit Hyperactivity Disorder (ADHD)[Label,A177181]. The d-isomer is thought to have greater effect with fewer side effects than the l-isomer or...
Approved
Investigational
Matched Description: … It is a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant[A177193]. …
Matched Categories: … Methylphenidate and isomer ... dexmethylphenidate and serdexmethylphenidate ... Psychostimulants, Agents Used for ADHD and Nootropics …

Dantrolene

Chemically, dantrolene is a hydantoin derivative, but does not exhibit antiepileptic activity like other hydantoin derivates such as phenytoin.
Approved
Investigational
Matched Categories: … Dantrolene and Derivatives …

Ecallantide

Ecallantide is a potent and selective human plasma kallikrein inhibitor that is indicated for the symptomatic treatment of hereditary angioedema. Ecallantide is a recombinant 60-amino-acid protein produced in Pichia pastoris yeast cells that contains three intramolecular disulfide bonds [FDA Label]. It was discovered by phage display technology . It shares...
Approved
Investigational
Matched Description: … The amino acid sequence of two compounds differ by seven amino acids [L1458]. ... Ecallantide is a recombinant 60-amino-acid protein produced in _Pichia pastoris_ yeast cells that contains ... activity of kallikrein and excessive bradykinin production [FDA Label]. …
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …
Displaying drugs 1976 - 2000 of 15273 in total